Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cemiplimab · Libtayo, REGN-2810

Monoclonal antibody · Antagonist of Programmed cell death protein 1 (PD-1) (PDCD1) · developed by Regeneron Pharmaceuticals

Approved FDA, Sep 2018
REGN Developer
3 Registered trials

What is Cemiplimab?

Cemiplimab is a recombinant human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells and blocks its interaction with PD-L1 and PD-L2, releasing PD-1-mediated inhibition of the anti-tumor immune response. It is studied in melanoma, colon cancer and Merkel cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Libtayo, REGN-2810, LIBTAYO
Drug type
Monoclonal antibody
Targets
Programmed cell death protein 1 (PD-1) (PDCD1), Programmed death-ligand 1 (PD-L1) (CD274) (binding partner it blocks)
Mechanism
Antagonist of Programmed cell death protein 1 (PD-1) (PDCD1)
Pathways
PD-1/PD-L1 immune checkpoint signaling, T-cell activation and anti-tumor immune response
Therapy area
Oncology
Developer
Regeneron Pharmaceuticals (REGN)
FDA status
Approved as Libtayo (September 28, 2018), BLA761097 · FDA label
UNII
6QVL057INT

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 31, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06246916 Phase 3 Melanoma Recruiting REGN
NCT07224022 Phase 2 Colon Cancer Not yet recruiting REGN
NCT07387198 Phase 2 Merkel Cell Carcinoma, Stage I Recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colon CancerMelanomaMerkel Cell Carcinoma, Stage IMerkel Cell Carcinoma, Stage IINeoadjuvant Immunotherapy

Other drugs acting on PDCD1

More from Regeneron Pharmaceuticals

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Cemiplimab

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.